WallStSmart

HCA Healthcare, Inc. (HCA)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 8581% more annual revenue ($76.39B vs $879.95M). NUTX leads profitability with a 11.0% profit margin vs 8.9%. NUTX trades at a lower P/E of 9.9x. NUTX earns a higher WallStSmart Score of 64/100 (C+).

HCA

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

NUTX

Buy

64

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 8.3Quality: 7.0
Piotroski: 4/9Altman Z: 2.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCASignificantly Overvalued (-85.7%)

Margin of Safety

-85.7%

Fair Value

$286.26

Current Price

$372.13

$85.87 premium

UndervaluedFair: $286.26Overvalued
NUTXUndervalued (+63.6%)

Margin of Safety

+63.6%

Fair Value

$283.22

Current Price

$135.10

$148.12 discount

UndervaluedFair: $283.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA4 strengths · Avg: 9.3/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.9110/10

Conservative balance sheet, low leverage

Market CapQuality
$80.58B9/10

Large-cap with strong market position

P/E RatioValuation
12.5x8/10

Attractively priced relative to earnings

NUTX5 strengths · Avg: 9.4/10
P/E RatioValuation
9.9x10/10

Attractively priced relative to earnings

Operating MarginProfitability
37.5%10/10

Strong operational efficiency at 37.5%

EPS GrowthGrowth
95.9%10/10

Earnings expanding 95.9% YoY

Return on EquityProfitability
27.8%9/10

Every $100 of equity generates 28 in profit

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

HCA2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

NUTX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Market CapQuality
$927.61M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.013/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.12 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, Altman Z-Score.

Bear Case : NUTX

The primary concerns for NUTX are Revenue Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

NUTX carries more volatility with a beta of 2.06 — expect wider price swings.

HCA is growing revenue faster at 4.3% — sustainability is the question.

HCA generates stronger free cash flow (895M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NUTX scores higher overall (64/100 vs 63/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?